Treatment of postmenopausal women with osteoporosis with PTH(184) for 36 months: Treatment extension study

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2627-2633

  Zanchetta, José R ^a   Bogado, Cesar E ^a   Cisari, Carlo ^b   Aslanidis, Spyros ^c   Greisen, Hanna ^d   Fox, John ^e   Lems, Willem ^f  

^a Instituto de Investigaciones Metabolicas   (Argentina)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c Aristotle University of Thessaloniki   (Greece)

^d Nycomed Denmark   (Denmark)

^e NPS Pharmaceuticals   (United States)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

84); Bone mineral density (BMD); Full length parathyroid hormone; Osteoporosis; PTH(1; Vertebral fracture

Indexed keywords

CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE; PLACEBO;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE LESION; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; HIP; HUMAN; HYPERCALCIURIA; ILIAC CREST; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OUTCOME ASSESSMENT (HEALTH CARE); PARATHYROID HORMONE; SPINE; TIME FACTORS;

EID: 77958131700     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.524121     Document Type: Article

References (13)

1. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-39
2. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmen-opausal osteoporosis. J Clin Endocrinol Metab 2003;88:5212-20
3. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
4. Recker RR, Bare SP, Smith SY, et al. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone 2009;44:113-19
5. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15
6. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe post-menopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009; 24:726-36
7. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34
8. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005; 353:555-65
9. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350:550-5
10. Devogelaer J-P, Warner M, Saag K, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: 36-months results. Osteoporos Int 2009;20:S7
11. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
12. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
13. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52